Welcome to our dedicated page for ELI LILLY & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ELI LILLY & Co's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ELI LILLY & Co's regulatory disclosures and financial reporting.
LUCIANO JUAN R reported acquisition or exercise transactions in this Form 4 filing.
ELI LILLY & Co director Juan R Luciano received a grant of 13.878 shares of common stock on 2026-07-20 at $1,146.9000 per share. These shares were deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in common shares after his separation from service. Following this award, he directly holds 16,904.5921 shares.
Fyrwald J Erik reported acquisition or exercise transactions in this Form 4 filing.
Eli Lilly director J Erik Fyrwald elected to receive 8.6465 shares’ worth of common stock on July 20, 2026 as deferred stock units in lieu of cash director compensation at $1,146.90 per share, bringing his direct holdings to 75,409.7433 shares, to be settled after his separation from service.
Alvarez Ralph reported acquisition or exercise transactions in this Form 4 filing.
ELI LILLY & Co director Ralph Alvarez received an award of 10.8263 common shares on 2026-07-20, valued at $1146.9000 per share. At his election, the award was deferred as stock units under the Lilly Directors' Deferral Plan, to be settled in shares after separation from service. Following this grant, he holds 55734.2935 shares directly and 758.0000 shares indirectly through a trust, for which he disclaims beneficial ownership beyond his pecuniary interest. The report indicates the transaction was not made under a Rule 10b5-1 trading plan.
The filer submitted a Form 144 notice reporting proposed sales of Eli Lilly and Company common stock by Lilly Endowment Inc. and related holders. The excerpt lists multiple sale dates between 05/06/2026 and 06/26/2026 with individual share quantities and gross proceeds for each trade.
Eli Lilly and Company-related holders reported proposed and completed sales of Common Stock. The excerpt lists a proposed sale of 38,400,000 shares attributed to the J.K. Lilly Sr. Trust and multiple completed dispositions by Lilly Endowment Inc., with dated transactions in May–June 2026 showing specific share counts and proceeds.
ELI LILLY & Co director Gabrielle Sulzberger received a stock-based compensation award rather than making an open-market trade. She acquired 4.3904 shares of common stock on an award basis at $1,129.35 per share, bringing her direct holdings to 2,995.3956 shares.
According to the company’s directors’ deferral program, she elected to defer this compensation into stock units under the Lilly Directors' Deferral Plan. These units will be settled in shares of common stock after she separates from board service, so this filing reflects a deferred equity award, not a cash salary payment or market purchase.
ELI LILLY & Co director Juan R. Luciano received a grant of 14.0937 shares of common stock at $1,129.35 per share. At his election, this award has been deferred as stock units under the Lilly Directors' Deferral Plan and will be settled in shares after his separation from service. Following this compensation-related acquisition, his direct holdings total 16,890.7141 shares of common stock.
Fyrwald J Erik reported acquisition or exercise transactions in this Form 4 filing.
ELI LILLY & Co director J Erik Fyrwald received a grant of 8.7809 shares of common stock equivalent on a deferred basis. The award was priced at $1,129.35 per share and was taken in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan. After this grant, Fyrwald holds a total of 75,401.0968 shares of Lilly common stock directly, including these deferred stock units, which will be settled in shares after his separation from service.
ELI LILLY & Co director Ralph Alvarez reported a compensation-related stock award, increasing his direct holdings. On June 15, 2026, he acquired 10.9945 shares of common stock at $1,129.35 per share, characterized as a grant or award rather than an open-market purchase.
According to the footnotes, these shares were deferred as stock units under the Lilly Directors' Deferral Plan in lieu of cash compensation and will be settled in common stock after he leaves the board. Following this award, Alvarez directly holds 55,723.4672 shares of common stock and indirectly holds 758 shares through a trust, where he disclaims beneficial ownership beyond his pecuniary interest.
ELI LILLY & Co executive Ilya Yuffa reported an insider sale of company stock. On June 10, 2026, Yuffa, EVP & President, LLY USA & Global Capabilities, completed an open-market sale of 2,500 shares of Eli Lilly common stock at an average price of $1,150.77 per share.
The transaction was carried out under a Rule 10b5-1 trading plan that Yuffa adopted on February 13, 2026, indicating it was pre-arranged. Following this sale, he directly holds 29,804.111 shares of Eli Lilly common stock.